Anavex Life Sciences Corp (AVXL)

[RedShoulder]

TempePhil, add to that the many severe adverse advents that Lilly'd drug produces with a drop out rate of 30.5 percent of patients discontinued treatment due to an adverse event and half of these discontinuations were due to ARIA-related events.

We are beating a dead horse, Lily's drug has no chance for FDA approval with the decline your graph shows, plus the multitude of adverse events along with the 30.5 drop out rate.

"The safety profile of donanemab was consistent with observations from Phase 1 data. In the donanemab treatment group, amyloid-related imaging abnormalities – edema (ARIA-E) occurred in 26.7 percent of treated participants, with an overall incidence of 6.1 percent experiencing symptomatic ARIA-E; the majority ARIA-E cases occurred within the first 12 weeks after initiation of treatment.

Other common AEs in the donanemab treatment group include ARIA-H related events like microhemorrhages (7.6 percent) and superficial siderosis of central nervous system (13.7 percent), nausea (10.7 percent), and infusion-related reaction (IRR) (7.6 percent). Serious IRR or hypersensitivity occurred in 2.3 percent of participants treated with donanemab. In the donanemab arm, 30.5 percent of patients discontinued treatment due to an adverse event and half of these discontinuations were due to ARIA-related events."

https://www.prnewswire.com/news-releases/lillys-donanemab-slowed-alzheimers-disease-progression-in-phase-2-trial-full-data-presented-at-adpd-2021-and-published-in-nejm-301246745.html